157 related articles for article (PubMed ID: 38473821)
21. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
[TBL] [Abstract][Full Text] [Related]
22. Atypical KRAS
Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
[TBL] [Abstract][Full Text] [Related]
23. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
24. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
25. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
26. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
28. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
29. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
[TBL] [Abstract][Full Text] [Related]
30. High-throughput, single-particle tracking reveals nested membrane domains that dictate KRas
Lee Y; Phelps C; Huang T; Mostofian B; Wu L; Zhang Y; Tao K; Chang YH; Stork PJ; Gray JW; Zuckerman DM; Nan X
Elife; 2019 Nov; 8():. PubMed ID: 31674905
[TBL] [Abstract][Full Text] [Related]
31. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
Krasinskas AM; Chiosea SI; Pal T; Dacic S
Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
[TBL] [Abstract][Full Text] [Related]
34. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
[TBL] [Abstract][Full Text] [Related]
35. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras
Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B
Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
37. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein.
Dai E; Han L; Liu J; Xie Y; Kroemer G; Klionsky DJ; Zeh HJ; Kang R; Wang J; Tang D
Autophagy; 2020 Nov; 16(11):2069-2083. PubMed ID: 31920150
[No Abstract] [Full Text] [Related]
38. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice.
Kimura Y; Fukuda A; Ogawa S; Maruno T; Takada Y; Tsuda M; Hiramatsu Y; Araki O; Nagao M; Yoshikawa T; Ikuta K; Yoshioka T; Wang Z; Akiyama H; Wright CV; Takaori K; Uemoto S; Chiba T; Seno H
Gastroenterology; 2018 Jul; 155(1):194-209.e2. PubMed ID: 29604291
[TBL] [Abstract][Full Text] [Related]
39. ANGPTL4 accelerates KRAS
Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
[TBL] [Abstract][Full Text] [Related]
40. Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP.
Xia Y; Zhang S; Luo H; Wang Y; Jiang Y; Jiang J; Yuan S
Eur J Pharmacol; 2023 Dec; 961():176157. PubMed ID: 37939992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
